ANALYSIS: Revolution may spring pharma opportunity in MENA
This article was originally published in Scrip
When Mohamed Bouazizi, a 26-year-old Tunisian fruit-and-vegetable seller, set himself alight almost two years ago, starting what has become known as The Arab Spring, few could have predicted that long-standing regimes would soon start toppling like dominoes.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.